Conducting PTSD clinical trials on a Schedule I drug: MDMA

OPEN Foundation
December 12, 2016

Knopf, A. (2016). Conducting PTSD clinical trials on a Schedule I drug: MDMA. Alcoholism & Drug Abuse Weekly, 28(47), 7-8. 10.1002/adaw.30797
Link to full text

OPEN Foundation

Share This Post

Clinical Trial into Psilocybin Therapy for Psychological Distress in Palliative Care, PsyPal, Receives Medical Ethical Authorisation, with Conditions

Comparing Psychedelic-Assisted Therapy with Traditional Therapy for Mental Illnesses – Part 2

Harnessing Psychedelics for Neurofeedback: A New Frontier in Executive Function Improvement

Psychedelics vs. Traditional Treatments —How Do They Stack Up for Mental Health Disorders? – Part 1

Dutch Psychedelic Practices Shaped by Culture and Law

Do Psychedelic States merely create comforting delusions?

Lessons on Psychedelic Harm Reduction with PsyCare NL – From the field

The Role of Psychedelics in Palliative Care: Real-World Cases – Dr. Houman Farzin, M.D.

The FDA’s Decision on MDMA-Assisted Psychotherapy: A Call for Pragmatism and Scientific Rigor

get the latest

The OPEN Minded Newsletter keeps you informed about the latest psychedelic research & news, articles, exclusive events, job opportunities, programmes, and free resources!

By clicking SUBSCRIBE, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.

Conducting PTSD clinical trials on a Schedule I drug: MDMA

OPEN Foundation

Share This Post

get the latest

OPEN

ABOUT

EVENTS

RESOURCES

PROGRAMMES

ACTIONS